title: [Optimal lipid treatment: possibilities and current limitations].
abstract: Prevention is a major contributor to the decline in cardiovascular morbidity and mortality. Cardiovascular diseases still are the leading cause of death (42%) in Germany and indicate unmet preventive needs. Limitations of healthy lifestyle, the basis of many recommendations, include insufficient compliance and efficacy in individual cases. In their latest metaanalysis the Cholesterol Treatment Trialists' Collaborators showed updated estimates of treatment effects of statins including more or less intensive regimens.The average reduction in major vascular events was 21% per 1.0 mmol/l reduction in LDL cholesterol. Appropriateness of receiving lipid modulating treatment in the population will be discussed in the light of controversial recommendations in treatment strategies. Residual risk in statin treated patients may be ameliorated by options beyond LDL-lowering. Suggestions for clinical practice are provided on the background of clinical relevant characteristics of current lipid lowering drugs and future developments are outlined.
authors.affiliation: Internistische Praxisgemeinschaft Dres. T. Beckenbauer, S. Maierhof, Hans-Thoma-Strasse 31, Bremen, Germany. klose.bremen@t-online.de
authors.forename: G
authors.initials: G
authors.lastname: Klose
mesh_terms: D000837:Anion Exchange Resins / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001781:Blood Component Removal; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D002423:Cause of Death; D008078:Cholesterol, LDL; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use; D058607:Fibric Acids / Q000009:adverse effects / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000401:mortality; D006951:Hyperlipoproteinemias / Q000188:drug therapy* / Q000401:mortality; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000401:mortality; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008019:Life Style; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000837:Anion Exchange Resins; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D015525:Fatty Acids, Omega-3; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin